Cue Biopharma, Inc.
CUE
$30.50
$0.501.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -321.93% | 51.89% | 34.60% | 15.53% | 17.17% |
| Total Depreciation and Amortization | 186.53% | 4.89% | -14.81% | -74.09% | -75.45% |
| Total Amortization of Deferred Charges | -48.65% | -24.32% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | 1,412.80% | -29.88% | -10.34% | -10.57% | -10.64% |
| Change in Net Operating Assets | -30.84% | -319.17% | 33.10% | 105.82% | 183.00% |
| Cash from Operations | -77.83% | 29.55% | 40.30% | 22.53% | 26.96% |
| Capital Expenditure | 32.02% | 8.07% | -168.18% | -179.69% | -173.85% |
| Sale of Property, Plant, and Equipment | -59.18% | -59.18% | -59.18% | -78.35% | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 263.75% | 265.08% | 134.38% | -21,148.48% | -101.62% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 37.48% | 12.48% | -12.53% | 0.03% | 0.03% |
| Issuance of Common Stock | 26.87% | 19.87% | -10.51% | -90.88% | -20.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 52.65% | -- | -- | -- | -- |
| Cash from Financing | 55.00% | 300.60% | 156.67% | -0.56% | 139.51% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -298.38% | 111.63% | 117.96% | 6.96% | 88.92% |